WASHINGTON (CN) - The Food and Drug Administration no longer will allow ozone-depleting substances to be used in certain inhaled medications.
The agency has concluded that there are no substantial technical barriers to formulating these medications without ozone-depleting substances, and the Clean Air Act requires the FDA determine which products are essential uses of the substances.
Effective June 14, metaproterenol and nedocromil may not be marketed containing ozone-depleting substances. Dec. 31, triamcinolone and cromolyn must not contain the substances. June 30, 2011 flunisolide must not contain the substances. Dec. 31, 2013, pirbuterol, and albuterol and ipratropium in combination must not contain the substances.
Click the document icon for this regulation and others.
Read the Top 8
Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.
Additional Reads
-
-
Opioid distributor's first-of-its-kind criminal trial opens in NYC January 18, 2022
-
Biden administration moves to curtail ‘forever chemicals’ October 18, 2021 -
New Mexico found to violate First Amendment right of access October 8, 2021